Antibodies Update as regards Covid-19

Since the start of the COVID-19 outbreak, the quest for finding antibodies has proceeded relentlessly. The team of professor Xavier Saelens, in close collaboration with the lab of Jason McLellan (University of Texas at Austin, US) have isolated and characterized a small antibody derived from llamas that binds an important part of the SARS-CoV-2 virus.

Their findings show exactly where the antibody binds to the virus’ S proteins. These proteins are of vital importance to the virus as they enable it to enter host cells. By targeting these proteins, the antibody can neutralize the virus. This is an important step forward in the pursuit of an antiviral drug against COVID-19.

En route to Protection

The new results provide the first evidence that the antibody could prevent the new coronavirus from infecting human cells. Importantly, the antibody can also be produced at large-scale using production processes that are common in the biopharmaceutical industry.

Prof. Saelens emphasizes: “This is a very important step forward in the fight against COVID-19, made possible by joining forces of my and Nico Callewaert’s team (VIB-UGent Center for Medical Biotechnology).”

Dr. Bert Schepens, staff scientist in the team of Prof. Saelens: “Good teamwork is crucial. We can count on the expertise in the research center, and colleagues from across VIB. Key to the progress we made is the long-standing collaboration with the labs of Jason Mclellan and Barney Graham. The moment we observed virus neutralization in these experiments really felt like a collective victory.”

In contrast to vaccines, an antibody offers immediate protection — though of shorter duration. The advantage of this approach over vaccines is that patients don’t need to produce their own antibodies. The most vulnerable groups, such as the elderly, often mount a modest response to vaccines, which means that their protection may be incomplete. Healthcare workers or people at increased risk of exposure to the virus can also benefit from an immediate protection. This type of medicine can therefore be an important tool in fighting the current pandemic.

The next step

The VIB researchers are preparing the preclinical test phase for a coronavirus treatment. Although these first results are highly promising, further research is necessary to confirm the full potential of this antibody-based drug directed against COVID-19. VIB’s Technology Transfer team together with researchers of VIB Discovery Sciences provide outstanding support en route to clinical development of this anti-COVID-19 drug candidate.

Source: VIB (the Flanders Institute for Biotechnology)

18 thoughts on “Antibodies Update as regards Covid-19

  1. 996221 712195Im often to blogging and i in actual fact respect your content. The piece has actually peaks my interest. Im going to bookmark your content and preserve checking for brand new details. 438095

  2. 968967 304481Very good post. I just stumbled upon your weblog and wanted to say that Ive truly enjoyed surfing about your weblog posts. Soon after all I will probably be subscribing to your feed and I hope you write again extremely soon! 167158

  3. 176885 193781We supply you with a table of all of the emoticons that can be used on this application, and the meaning of each symbol. Though it might take some initial effort on your part, the skills garnered from regular and strategic use of social media will create a strong foundation to grow your business on ALL levels. 155144

  4. 845152 606071Hello. Cool write-up. Theres an concern with the website in internet explorer, and you might want to test this The browser may be the marketplace chief and a large element of other folks will miss your excellent writing due to this issue. 917442

  5. 960616 935117I like the valuable details you provide within your articles. Ill bookmark your blog and check once more here often. Im quite certain I will learn plenty of new stuff correct here! Excellent luck for the next! 360136

Leave a Reply

Your email address will not be published. Required fields are marked *